Radiomic Signatures Based on Pretreatment 18F-FDG PET/CT, Combined With Clinicopathological Characteristics, as Early Prognostic Biomarkers Among Patients With Invasive Breast Cancer

Development and Validation of a Novel TNM Staging N-Classification of Oral Cavity Squamous Cell Carcinoma

Utilizing Biomarkers to Optimize Treatment for Upper Gastrointestinal Cancers

Survival Benefit With Checkpoint Inhibitors Versus Chemotherapy is Modified by Brain Metastases in Patients With Recurrent Small-Cell Lung Cancer

Evaluating Strategies and Approaches to Prevent Graft-Versus-Host Disease

ChatGPT's Limited Ability to Recommend Guideline-Based Cancer Treatments

Response Assessment of Post-Treatment Head and Neck Cancers to Determine Further Management Using NI-RADS (Neck Imaging Reporting and Data System): A Subgroup Analysis of a Randomized Controlled Trial

IDEAYA Biosciences Receives Fast Track Designation for IDE161 in a Second Indication for the Treatment of Pretreated, Advanced or Metastatic HR+, HER2-, BRCA1/2 Mutant Breast Cancer

Radiomic Signatures Based on Pretreatment 18F-FDG PET/CT, Combined With Clinicopathological Characteristics, as Early Prognostic Biomarkers Among Patients With Invasive Breast Cancer

header-info

Aug, 07, 2023

In this study, researchers developed a clinicopathologic-radiomic based model and established a clinical nomogram to investigate the predictive role of fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography as prognostic risk stratification among patients with invasive breast cancer.

Access the full article to read more here.